Investigating how a new antibody treatment affects bone healing in patients with brittle bone disorder.
Biomarking the Sclerostin Antibody Effects on Osseointegration in an Osteogenesis Imperfecta Model
This study is looking at a new treatment for people with Osteogenesis Imperfecta (OI) to see if Sclerostin Antibodies can help strengthen bones and improve healing, especially for those needing dental implants, while also exploring how certain markers in the body can help tailor the treatment to each patient.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10878856 on NIH RePORTER |
What this research studies
This research focuses on Osteogenesis Imperfecta (OI), a genetic condition that leads to fragile bones and frequent fractures. The study explores the effects of a novel treatment using Sclerostin Antibodies, which aim to enhance bone density and healing, particularly in the jaw area where dental implants are placed. By cycling the treatment with breaks, the researchers hope to optimize bone formation and improve outcomes for patients needing dental implants. Additionally, the study will investigate the use of MicroRNAs as biomarkers to better understand and personalize treatment for OI patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Osteogenesis Imperfecta who may require dental implants or have concerns about bone density.
Not a fit: Patients without Osteogenesis Imperfecta or those who do not require dental implants may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved bone healing and stability for patients with Osteogenesis Imperfecta, particularly in relation to dental implants.
How similar studies have performed: Previous research has shown promising results with Sclerostin Antibodies in enhancing bone density, but this specific approach in the context of Osteogenesis Imperfecta and dental implants is relatively novel.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Sung Hsieh, Hsiao Hsin — University of Michigan at Ann Arbor
- Study coordinator: Sung Hsieh, Hsiao Hsin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.